Development of a new tandem mass spectrometry method for urine and amniotic fluid screening of oligosaccharidoses
Rationale The first step in the diagnosis of oligosaccharidoses is to evidence abnormal oligosaccharides excreted in urine, usually performed by the poorly sensitive but efficient thin layer chromatography (TLC) method. Developing a tandem mass spectrometry (MS/MS) technique could be of great intere...
Gespeichert in:
Veröffentlicht in: | Rapid communications in mass spectrometry 2017-06, Vol.31 (11), p.951-963 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 963 |
---|---|
container_issue | 11 |
container_start_page | 951 |
container_title | Rapid communications in mass spectrometry |
container_volume | 31 |
creator | Piraud, Monique Pettazzoni, Magali Menegaut, Louise Caillaud, Catherine Nadjar, Yann Vianey‐Saban, Christine Froissart, Roseline |
description | Rationale
The first step in the diagnosis of oligosaccharidoses is to evidence abnormal oligosaccharides excreted in urine, usually performed by the poorly sensitive but efficient thin layer chromatography (TLC) method. Developing a tandem mass spectrometry (MS/MS) technique could be of great interest to replace TLC.
Methods
Abnormal underivatized oligosaccharides have been recently studied using matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry, allowing the unambiguous identification of oligosaccharidoses. Based on this previous work, we developed an advantageous and efficient liquid chromatography (LC)/MS/MS method using a more common triple quadrupole tandem mass spectrometer for oligosaccharides analysis.
Results
Oligosaccharidoses (n = 97) and control (n = 240) urine samples were analysed. A specific pattern was obtained for each oligosaccharidosis using this method. In urine, it allows not only the identification of all the oligosaccharidoses previously identified by TLC (fucosidosis, alphamannosidosis, aspartylglucosaminuria, GM1 gangliosidosis, sialidosis, galactosialidosis and Schindler disease), but also extends the field of diagnosis to mucolipidosis type II, Sandhoff disease, and β‐mannosidosis. The same technique was applied to 16 amniotic fluid supernatants from oligosaccharidosis‐affected foetuses (n = 16) compared with 37 unaffected. All the affected foetuses could be clearly identified: sialidosis (n = 3), galactosialidosis (n = 4), aspartylglucosaminuria (n = 1), mucolipidosis type II (n = 4) or GM1 gangliosidosis (n = 4). This technique can be applied to early prenatal diagnosis as well as to the oligosaccharidosis screening in the case of non‐immune hydrops fetalis.
Conclusions
The method is quick and easy to run, with an LC analysis time of 13 min per sample. The quantitative validation could not be obtained in the absence of a specific standard and of a labelled internal standard for each compound. Even if this LC/MS/MS method is only qualitative, it is very specific and much more sensitive than TLC. It allows the urinary screening of oligosaccharidoses, even mild or late‐onset forms, and the screening of antenatal forms in amniotic fluid. Copyright © 2017 John Wiley & Sons, Ltd. |
doi_str_mv | 10.1002/rcm.7860 |
format | Article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01848141v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1901448579</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4490-3ab73c7019dbac37e4aece99fef7e67e28c484eb603d31a2a160a69b72ab3b2a3</originalsourceid><addsrcrecordid>eNp1kcFq3DAQQEVpaDZpoV9QBL00B6caS2tJx7BpksKWQmnPYiyPswq2tZHshP37ertpCoVcNCAejxkeY-9BnIMQ5efk-3NtKvGKLUBYXYhSwmu2EHYJhQJrjtlJzndCACxL8YYdl0ZqsZSwYPeX9EBd3PY0jDy2HPlAj3zEoaGe95gzz1vyY4o9jWnH53cTG97GxKcUBuIzyLEfQhyD5203hYZnn4iGMNzufbELtzGj9xtMoYmZ8lt21GKX6d3TPGW_rr78XN0U6-_XX1cX68IrZUUhsdbSawG2qdFLTQrJk7UttZoqTaXxyiiqKyEbCVgiVAIrW-sSa1mXKE_Z2cG7wc5tU-gx7VzE4G4u1m7_J8AoAwoeYGY_HdhtivcT5dH1IXvqOhwoTtmBMQoqo42Z0Y__oXdxSsN8iQMrQCmz1Paf0KeYc6L2eQMQbp_MzcncPtmMfngSTnVPzTP4t9EMFAfgMXS0e1Hkfqy-_RH-Bt4NoEw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901448579</pqid></control><display><type>article</type><title>Development of a new tandem mass spectrometry method for urine and amniotic fluid screening of oligosaccharidoses</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Piraud, Monique ; Pettazzoni, Magali ; Menegaut, Louise ; Caillaud, Catherine ; Nadjar, Yann ; Vianey‐Saban, Christine ; Froissart, Roseline</creator><creatorcontrib>Piraud, Monique ; Pettazzoni, Magali ; Menegaut, Louise ; Caillaud, Catherine ; Nadjar, Yann ; Vianey‐Saban, Christine ; Froissart, Roseline</creatorcontrib><description>Rationale
The first step in the diagnosis of oligosaccharidoses is to evidence abnormal oligosaccharides excreted in urine, usually performed by the poorly sensitive but efficient thin layer chromatography (TLC) method. Developing a tandem mass spectrometry (MS/MS) technique could be of great interest to replace TLC.
Methods
Abnormal underivatized oligosaccharides have been recently studied using matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry, allowing the unambiguous identification of oligosaccharidoses. Based on this previous work, we developed an advantageous and efficient liquid chromatography (LC)/MS/MS method using a more common triple quadrupole tandem mass spectrometer for oligosaccharides analysis.
Results
Oligosaccharidoses (n = 97) and control (n = 240) urine samples were analysed. A specific pattern was obtained for each oligosaccharidosis using this method. In urine, it allows not only the identification of all the oligosaccharidoses previously identified by TLC (fucosidosis, alphamannosidosis, aspartylglucosaminuria, GM1 gangliosidosis, sialidosis, galactosialidosis and Schindler disease), but also extends the field of diagnosis to mucolipidosis type II, Sandhoff disease, and β‐mannosidosis. The same technique was applied to 16 amniotic fluid supernatants from oligosaccharidosis‐affected foetuses (n = 16) compared with 37 unaffected. All the affected foetuses could be clearly identified: sialidosis (n = 3), galactosialidosis (n = 4), aspartylglucosaminuria (n = 1), mucolipidosis type II (n = 4) or GM1 gangliosidosis (n = 4). This technique can be applied to early prenatal diagnosis as well as to the oligosaccharidosis screening in the case of non‐immune hydrops fetalis.
Conclusions
The method is quick and easy to run, with an LC analysis time of 13 min per sample. The quantitative validation could not be obtained in the absence of a specific standard and of a labelled internal standard for each compound. Even if this LC/MS/MS method is only qualitative, it is very specific and much more sensitive than TLC. It allows the urinary screening of oligosaccharidoses, even mild or late‐onset forms, and the screening of antenatal forms in amniotic fluid. Copyright © 2017 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0951-4198</identifier><identifier>EISSN: 1097-0231</identifier><identifier>DOI: 10.1002/rcm.7860</identifier><identifier>PMID: 28370531</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Amniotic Fluid - chemistry ; Chromatography ; Desorption ; Diagnosis ; Female ; Fetuses ; Humans ; Ionization ; Ions ; Lasers ; Life Sciences ; Linear Models ; Lysosomal Storage Diseases - diagnosis ; Mass spectrometry ; Oligosaccharides ; Oligosaccharides - analysis ; Oligosaccharides - chemistry ; Oligosaccharides - urine ; Prenatal Diagnosis - methods ; Quadrupoles ; Reproducibility of Results ; Scientific imaging ; Screening ; Sensitivity and Specificity ; Spectroscopy ; Tandem Mass Spectrometry - methods ; Thin layer chromatography ; Urine</subject><ispartof>Rapid communications in mass spectrometry, 2017-06, Vol.31 (11), p.951-963</ispartof><rights>Copyright © 2017 John Wiley & Sons, Ltd.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4490-3ab73c7019dbac37e4aece99fef7e67e28c484eb603d31a2a160a69b72ab3b2a3</citedby><cites>FETCH-LOGICAL-c4490-3ab73c7019dbac37e4aece99fef7e67e28c484eb603d31a2a160a69b72ab3b2a3</cites><orcidid>0000-0002-2341-6514</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Frcm.7860$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Frcm.7860$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,315,782,786,887,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28370531$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01848141$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Piraud, Monique</creatorcontrib><creatorcontrib>Pettazzoni, Magali</creatorcontrib><creatorcontrib>Menegaut, Louise</creatorcontrib><creatorcontrib>Caillaud, Catherine</creatorcontrib><creatorcontrib>Nadjar, Yann</creatorcontrib><creatorcontrib>Vianey‐Saban, Christine</creatorcontrib><creatorcontrib>Froissart, Roseline</creatorcontrib><title>Development of a new tandem mass spectrometry method for urine and amniotic fluid screening of oligosaccharidoses</title><title>Rapid communications in mass spectrometry</title><addtitle>Rapid Commun Mass Spectrom</addtitle><description>Rationale
The first step in the diagnosis of oligosaccharidoses is to evidence abnormal oligosaccharides excreted in urine, usually performed by the poorly sensitive but efficient thin layer chromatography (TLC) method. Developing a tandem mass spectrometry (MS/MS) technique could be of great interest to replace TLC.
Methods
Abnormal underivatized oligosaccharides have been recently studied using matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry, allowing the unambiguous identification of oligosaccharidoses. Based on this previous work, we developed an advantageous and efficient liquid chromatography (LC)/MS/MS method using a more common triple quadrupole tandem mass spectrometer for oligosaccharides analysis.
Results
Oligosaccharidoses (n = 97) and control (n = 240) urine samples were analysed. A specific pattern was obtained for each oligosaccharidosis using this method. In urine, it allows not only the identification of all the oligosaccharidoses previously identified by TLC (fucosidosis, alphamannosidosis, aspartylglucosaminuria, GM1 gangliosidosis, sialidosis, galactosialidosis and Schindler disease), but also extends the field of diagnosis to mucolipidosis type II, Sandhoff disease, and β‐mannosidosis. The same technique was applied to 16 amniotic fluid supernatants from oligosaccharidosis‐affected foetuses (n = 16) compared with 37 unaffected. All the affected foetuses could be clearly identified: sialidosis (n = 3), galactosialidosis (n = 4), aspartylglucosaminuria (n = 1), mucolipidosis type II (n = 4) or GM1 gangliosidosis (n = 4). This technique can be applied to early prenatal diagnosis as well as to the oligosaccharidosis screening in the case of non‐immune hydrops fetalis.
Conclusions
The method is quick and easy to run, with an LC analysis time of 13 min per sample. The quantitative validation could not be obtained in the absence of a specific standard and of a labelled internal standard for each compound. Even if this LC/MS/MS method is only qualitative, it is very specific and much more sensitive than TLC. It allows the urinary screening of oligosaccharidoses, even mild or late‐onset forms, and the screening of antenatal forms in amniotic fluid. Copyright © 2017 John Wiley & Sons, Ltd.</description><subject>Amniotic Fluid - chemistry</subject><subject>Chromatography</subject><subject>Desorption</subject><subject>Diagnosis</subject><subject>Female</subject><subject>Fetuses</subject><subject>Humans</subject><subject>Ionization</subject><subject>Ions</subject><subject>Lasers</subject><subject>Life Sciences</subject><subject>Linear Models</subject><subject>Lysosomal Storage Diseases - diagnosis</subject><subject>Mass spectrometry</subject><subject>Oligosaccharides</subject><subject>Oligosaccharides - analysis</subject><subject>Oligosaccharides - chemistry</subject><subject>Oligosaccharides - urine</subject><subject>Prenatal Diagnosis - methods</subject><subject>Quadrupoles</subject><subject>Reproducibility of Results</subject><subject>Scientific imaging</subject><subject>Screening</subject><subject>Sensitivity and Specificity</subject><subject>Spectroscopy</subject><subject>Tandem Mass Spectrometry - methods</subject><subject>Thin layer chromatography</subject><subject>Urine</subject><issn>0951-4198</issn><issn>1097-0231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFq3DAQQEVpaDZpoV9QBL00B6caS2tJx7BpksKWQmnPYiyPswq2tZHshP37ertpCoVcNCAejxkeY-9BnIMQ5efk-3NtKvGKLUBYXYhSwmu2EHYJhQJrjtlJzndCACxL8YYdl0ZqsZSwYPeX9EBd3PY0jDy2HPlAj3zEoaGe95gzz1vyY4o9jWnH53cTG97GxKcUBuIzyLEfQhyD5203hYZnn4iGMNzufbELtzGj9xtMoYmZ8lt21GKX6d3TPGW_rr78XN0U6-_XX1cX68IrZUUhsdbSawG2qdFLTQrJk7UttZoqTaXxyiiqKyEbCVgiVAIrW-sSa1mXKE_Z2cG7wc5tU-gx7VzE4G4u1m7_J8AoAwoeYGY_HdhtivcT5dH1IXvqOhwoTtmBMQoqo42Z0Y__oXdxSsN8iQMrQCmz1Paf0KeYc6L2eQMQbp_MzcncPtmMfngSTnVPzTP4t9EMFAfgMXS0e1Hkfqy-_RH-Bt4NoEw</recordid><startdate>20170615</startdate><enddate>20170615</enddate><creator>Piraud, Monique</creator><creator>Pettazzoni, Magali</creator><creator>Menegaut, Louise</creator><creator>Caillaud, Catherine</creator><creator>Nadjar, Yann</creator><creator>Vianey‐Saban, Christine</creator><creator>Froissart, Roseline</creator><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><scope>JQ2</scope><scope>L7M</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-2341-6514</orcidid></search><sort><creationdate>20170615</creationdate><title>Development of a new tandem mass spectrometry method for urine and amniotic fluid screening of oligosaccharidoses</title><author>Piraud, Monique ; Pettazzoni, Magali ; Menegaut, Louise ; Caillaud, Catherine ; Nadjar, Yann ; Vianey‐Saban, Christine ; Froissart, Roseline</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4490-3ab73c7019dbac37e4aece99fef7e67e28c484eb603d31a2a160a69b72ab3b2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Amniotic Fluid - chemistry</topic><topic>Chromatography</topic><topic>Desorption</topic><topic>Diagnosis</topic><topic>Female</topic><topic>Fetuses</topic><topic>Humans</topic><topic>Ionization</topic><topic>Ions</topic><topic>Lasers</topic><topic>Life Sciences</topic><topic>Linear Models</topic><topic>Lysosomal Storage Diseases - diagnosis</topic><topic>Mass spectrometry</topic><topic>Oligosaccharides</topic><topic>Oligosaccharides - analysis</topic><topic>Oligosaccharides - chemistry</topic><topic>Oligosaccharides - urine</topic><topic>Prenatal Diagnosis - methods</topic><topic>Quadrupoles</topic><topic>Reproducibility of Results</topic><topic>Scientific imaging</topic><topic>Screening</topic><topic>Sensitivity and Specificity</topic><topic>Spectroscopy</topic><topic>Tandem Mass Spectrometry - methods</topic><topic>Thin layer chromatography</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Piraud, Monique</creatorcontrib><creatorcontrib>Pettazzoni, Magali</creatorcontrib><creatorcontrib>Menegaut, Louise</creatorcontrib><creatorcontrib>Caillaud, Catherine</creatorcontrib><creatorcontrib>Nadjar, Yann</creatorcontrib><creatorcontrib>Vianey‐Saban, Christine</creatorcontrib><creatorcontrib>Froissart, Roseline</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Rapid communications in mass spectrometry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Piraud, Monique</au><au>Pettazzoni, Magali</au><au>Menegaut, Louise</au><au>Caillaud, Catherine</au><au>Nadjar, Yann</au><au>Vianey‐Saban, Christine</au><au>Froissart, Roseline</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a new tandem mass spectrometry method for urine and amniotic fluid screening of oligosaccharidoses</atitle><jtitle>Rapid communications in mass spectrometry</jtitle><addtitle>Rapid Commun Mass Spectrom</addtitle><date>2017-06-15</date><risdate>2017</risdate><volume>31</volume><issue>11</issue><spage>951</spage><epage>963</epage><pages>951-963</pages><issn>0951-4198</issn><eissn>1097-0231</eissn><abstract>Rationale
The first step in the diagnosis of oligosaccharidoses is to evidence abnormal oligosaccharides excreted in urine, usually performed by the poorly sensitive but efficient thin layer chromatography (TLC) method. Developing a tandem mass spectrometry (MS/MS) technique could be of great interest to replace TLC.
Methods
Abnormal underivatized oligosaccharides have been recently studied using matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry, allowing the unambiguous identification of oligosaccharidoses. Based on this previous work, we developed an advantageous and efficient liquid chromatography (LC)/MS/MS method using a more common triple quadrupole tandem mass spectrometer for oligosaccharides analysis.
Results
Oligosaccharidoses (n = 97) and control (n = 240) urine samples were analysed. A specific pattern was obtained for each oligosaccharidosis using this method. In urine, it allows not only the identification of all the oligosaccharidoses previously identified by TLC (fucosidosis, alphamannosidosis, aspartylglucosaminuria, GM1 gangliosidosis, sialidosis, galactosialidosis and Schindler disease), but also extends the field of diagnosis to mucolipidosis type II, Sandhoff disease, and β‐mannosidosis. The same technique was applied to 16 amniotic fluid supernatants from oligosaccharidosis‐affected foetuses (n = 16) compared with 37 unaffected. All the affected foetuses could be clearly identified: sialidosis (n = 3), galactosialidosis (n = 4), aspartylglucosaminuria (n = 1), mucolipidosis type II (n = 4) or GM1 gangliosidosis (n = 4). This technique can be applied to early prenatal diagnosis as well as to the oligosaccharidosis screening in the case of non‐immune hydrops fetalis.
Conclusions
The method is quick and easy to run, with an LC analysis time of 13 min per sample. The quantitative validation could not be obtained in the absence of a specific standard and of a labelled internal standard for each compound. Even if this LC/MS/MS method is only qualitative, it is very specific and much more sensitive than TLC. It allows the urinary screening of oligosaccharidoses, even mild or late‐onset forms, and the screening of antenatal forms in amniotic fluid. Copyright © 2017 John Wiley & Sons, Ltd.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28370531</pmid><doi>10.1002/rcm.7860</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-2341-6514</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0951-4198 |
ispartof | Rapid communications in mass spectrometry, 2017-06, Vol.31 (11), p.951-963 |
issn | 0951-4198 1097-0231 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_01848141v1 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Amniotic Fluid - chemistry Chromatography Desorption Diagnosis Female Fetuses Humans Ionization Ions Lasers Life Sciences Linear Models Lysosomal Storage Diseases - diagnosis Mass spectrometry Oligosaccharides Oligosaccharides - analysis Oligosaccharides - chemistry Oligosaccharides - urine Prenatal Diagnosis - methods Quadrupoles Reproducibility of Results Scientific imaging Screening Sensitivity and Specificity Spectroscopy Tandem Mass Spectrometry - methods Thin layer chromatography Urine |
title | Development of a new tandem mass spectrometry method for urine and amniotic fluid screening of oligosaccharidoses |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T18%3A57%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20new%20tandem%20mass%20spectrometry%20method%20for%20urine%20and%20amniotic%20fluid%20screening%20of%20oligosaccharidoses&rft.jtitle=Rapid%20communications%20in%20mass%20spectrometry&rft.au=Piraud,%20Monique&rft.date=2017-06-15&rft.volume=31&rft.issue=11&rft.spage=951&rft.epage=963&rft.pages=951-963&rft.issn=0951-4198&rft.eissn=1097-0231&rft_id=info:doi/10.1002/rcm.7860&rft_dat=%3Cproquest_hal_p%3E1901448579%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901448579&rft_id=info:pmid/28370531&rfr_iscdi=true |